Stock Events

Stock Events

Ascendis Pharma A/S 

M$4,270.00
0
+M$0.00+0% Tuesday 15:35

Statistics

Day High
4,270
Day Low
4,270
52W High
4,270
52W Low
4,270
Volume
0
Avg. Volume
3
Mkt Cap
280.08B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q1 2026
Q2 2026
Next
3.24
67.11
130.97
194.84
Expected EPS
18.525473415495203
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ASND1N.MX. It's not an investment recommendation.
Microsoft
12
MSFT
NVIDIA
12
NVDA
Apple
8
AAPL
Abbvie
8
ABBV

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap137.76B
Pfizer competes in various therapeutic areas including those targeted by Ascendis Pharma's endocrinology and oncology pipeline.
Novo Nordisk
NVO
Mkt Cap218.94B
Novo Nordisk is a leader in diabetes and growth disorders, directly competing with Ascendis Pharma's growth hormone deficiency treatments.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly has a strong presence in endocrinology, particularly in growth hormone and diabetes treatments, competing with Ascendis' portfolio.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals competes in the development of treatments for genetic disorders, a key area of focus for Ascendis Pharma.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical focuses on rare diseases, including areas like growth disorders, directly competing with Ascendis' therapies.
Opko Health
OPK
Mkt Cap1.02B
OPKO Health has a division focused on pharmaceuticals, including growth hormone treatments, making it a direct competitor.
Ligand Pharmaceuticals
LGND
Mkt Cap6.34B
Ligand Pharmaceuticals' technology platforms and partnerships enable it to compete in the development of endocrinology and oncology drugs.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals competes in the biopharmaceutical space with a focus on innovative treatments, overlapping with Ascendis' therapeutic areas.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on neurological and neurodegenerative diseases but its expansion into other biopharmaceutical areas can position it as a competitor.
AMGEN
AMGN
Mkt Cap196.12B
Amgen's broad focus on biotechnology treatments for various diseases, including bone health and oncology, places it in competition with Ascendis Pharma.

About

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Show more...
CEO
Mr. Jan Moller Mikkelsen
Employees
639
Country
Denmark
ISIN
DK0060615755
WKN
000A14M6X

Listings

SA
BR
A1SN34.SA
MX
MX
ASND1N.MX
STU
DE
A71.STU
MU
DE
A710.MU

0 Comments

Share your thoughts

FAQ

What is Ascendis Pharma A/S stock price today?▼
The current price of ASND1N.MX is M$4,270.00 MXN — it has increased by +0% in the past 24 hours. Watch Ascendis Pharma A/S stock price performance more closely on the chart.
What is Ascendis Pharma A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Mexican Exchange exchange Ascendis Pharma A/S stocks are traded under the ticker ASND1N.MX.
What is Ascendis Pharma A/S market cap?▼
Today Ascendis Pharma A/S has the market capitalization of 280.08B
When is the next Ascendis Pharma A/S earnings date?▼
Ascendis Pharma A/S is going to release the next earnings report on November 11, 2026.
What were Ascendis Pharma A/S earnings last quarter?▼
ASND1N.MX earnings for the last quarter are 55.03 MXN per share, whereas the estimation was 29.1 MXN resulting in a +89.09% surprise. The estimated earnings for the next quarter are N/A MXN per share.
How many employees does Ascendis Pharma A/S have?▼
As of August 15, 2026, the company has 639 employees.
In which sector is Ascendis Pharma A/S located?▼
Ascendis Pharma A/S operates in the Health & Wellness sector.
When did Ascendis Pharma A/S complete a stock split?▼
Ascendis Pharma A/S has not had any recent stock splits.
Where is Ascendis Pharma A/S headquartered?▼
Ascendis Pharma A/S is headquartered in Hellerup, Denmark.